Mallinckrodt's unfocused acquisition strategy increases uncertainty about future cash flows.
We may slightly lower our fair value estimate for Mallinckrodt as we make slight adjustments to our Therakos product line revenue, moderately decrease our margin assumptions, and incorporate the recently announced InfaCare Acquisition into our model. Management anticipates $0.15-$0.20 in adjusted EPS dilution this year along with a slight increase next year from higher operating costs in preparation of launching InfaCare’s severe jaundice drug, stannsoporfin, next year. The InfaCare deal helps i...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.